Clinical Trials on Premenopausal Breast Cancer in Japan
Total 1177 results
-
M.D. Anderson Cancer CenterTerminatedBreast CancerUnited States, Japan
-
Novartis PharmaceuticalsChugai PharmaceuticalCompletedPostmenopausal Women With Advanced Breast CancerJapan
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanCompletedBreast Cancer | Neoplasm MetastasisJapan
-
Novartis PharmaceuticalsTerminatedAdvanced or Metastatic ER+ Breast CancerUnited States, France, Germany, Singapore, Italy, Japan, Belgium
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
HekabioCompletedBreast Cancer | Head and Neck CancerJapan
-
Novartis PharmaceuticalsTerminatedTriple Negative Breast Cancer (TNBC)Netherlands, Spain, Hong Kong, Singapore, Italy, Australia, Israel, Japan, United States
-
Novartis PharmaceuticalsActive, not recruiting
-
PfizerCompleted
-
R-PharmCompleted
-
Daiichi Sankyo Co., Ltd.Daiichi Sankyo, Inc.CompletedMetastatic Breast CancerUnited States, Japan
-
Novartis PharmaceuticalsCompletedEsophageal Cancer | Triple Negative Breast Cancer | Head & Neck CancerFrance, Singapore, Italy, Japan, United States, Spain
-
AstraZenecaCompletedAdvanced Breast Cancer | Metastatic Breast CancerJapan
-
Ludwig Institute for Cancer ResearchMie UniversityCompletedStomach Cancer | Breast Cancer | Esophageal Cancer | Ovarian Cancer | Lung CancerJapan
-
Kyoto Breast Cancer Research NetworkPfizerCompletedHormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer FemaleTaiwan, Japan, Korea, Republic of, Australia, Hong Kong
-
AstraZenecaCompleted
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
GlaxoSmithKlineCompleted
-
Novartis PharmaceuticalsChugai PharmaceuticalCompletedPostmenopausal Women With Advanced Breast CancerJapan
-
PfizerCompleted
-
Novartis PharmaceuticalsCompletedTriple-negative Breast CancerBelgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
PfizerArvinas Estrogen Receptor, Inc.RecruitingBreast CancerUnited States, Japan, Puerto Rico
-
PfizerActive, not recruitingBreast CancerJapan, Korea, Republic of, Taiwan
-
Federal University of São PauloEmory University; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; University... and other collaboratorsActive, not recruitingBreast CancerBrazil, Canada, Italy, Japan
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.RecruitingTriple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast CancerUnited States, Japan
-
AstraZenecaDaiichi Sankyo, Inc.CompletedBreast CancerUnited States, Germany, Italy, Korea, Republic of, United Kingdom, Portugal, Australia, Japan, Canada, France
-
Kyowa Kirin Co., Ltd.CompletedAdvanced or Recurrent Breast CancerJapan
-
PfizerActive, not recruitingHR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast CancerUnited States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
-
Eli Lilly and CompanyTerminatedHepatocellular Carcinoma | Solid Tumor | Gastric Adenocarcinoma | Leiomyosarcoma | Head and Neck Squamous Cell Carcinoma | Cervical Carcinoma | Triple-negative Breast Cancer | Undifferentiated Pleomorphic Sarcoma | High Grade Serous Ovarian CarcinomaUnited States, Japan
-
Hoffmann-La RocheCompletedTriple-negative Breast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Belgium, Brazil, Germany, Taiwan, Australia, Japan, Spain, Poland, Italy
-
PfizerJapan Breast Cancer Research Group (JBCRG)Completed
-
GlaxoSmithKlineCompletedNeoplasms, BreastJapan
-
GlaxoSmithKlineCompleted
-
AbbVieTerminatedCancer | Breast CancerUnited States, Germany, Japan, Puerto Rico
-
Eisai Co., Ltd.Active, not recruiting
-
Translational Research Center for Medical Innovation...Department of breast and endocrine surgery graduate school of Medicine Osaka...Terminated
-
Hoffmann-La RocheTerminatedBreast CancerUnited States, Brazil, Australia, Canada, Japan, Korea, Republic of, Spain, United Kingdom
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerFrance, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
-
Novartis PharmaceuticalsRecruitingMetastatic Breast CancerUnited States, Lebanon, Hong Kong, Turkey, Vietnam, Brazil, Italy, South Africa, Korea, Republic of, Poland, Taiwan, Singapore, Japan, Spain, Costa Rica, Greece, Portugal, Argentina, Mexico
-
GlaxoSmithKlineCompleted
-
Eisai Inc.Bliss Biopharmaceutical (Hangzhou) Co., LtdRecruiting
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive Breast CancerUnited States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
-
Comprehensive Support Project for Oncology ResearchActive, not recruitingStomach Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Endometrial Cancer | Liver CancerJapan
-
Japan Breast Cancer Research NetworkTerminatedBreast NeoplasmsJapan
-
AstraZenecaRecruiting
-
Hoffmann-La RocheCompletedEarly Breast CancerFrance, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine